Hint mode is switched on Switch off
For swift navigation between sections

Lunai Bioworks

PDF download

Choose all Reset all
Download Cancel
Organization name
Lunai Bioworks Inc.
Country name
USA
Country of registration
USA
Industry
Pharmaceutical Preparation and Biotechnology
Public debt
-

Upgrade to Premium features

Cbonds consolidates global bond, stock, ETF and indices data into a single platform — so you can analyze faster, make informed investment decisions and outperform the market

Get access
Welcome to Cbonds

  • Full access to the largest bond database

    Bond parameters,
    prospectuses

  • Seamless
    Data export

    Analyze the data in the most efficient way

  • Bond pricing

    Current & historical quotes from 400+ stock exchanges & OTC market

  • Smart risk assessment

    Credit ratings, financial reports

Get access

Latest data on

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Quotes

Request sent
Access denied
Send request
Quotes provided by information providers are indicative in nature

Profile

Lunai Bioworks, Inc., formerly Renovaro Inc., is focused on AI-powered biodefense, drug discovery and advanced diagnostics. The Company is engaged in harnessing advanced computational biology and AI/machine learning to accelerate drug discovery, diagnostics and strengthen biosecurity capabilities. From high-resolution phenotyping to predictive disease modeling, the Company is pioneering a new era of precision diagnostics-where early detection, patient stratification, and therapeutic targeting converge into a single, adaptive platform. These are designed to transform clinical decision-making, reduce time-to-treatment, and unlock previously inaccessible insights from biological data. Its proprietary platforms in translational analytics, in vivo modeling, and machine vision-accelerating biomarker discovery and therapeutic development in precision neurology and infectious disease.

Awards

News

08/05/2026 Lunai Bioworks: Submission Of Matters To A Vote Of Security Holders
27/04/2026 Lunai Bioworks: Other Events, Financial Statements And Exhibits
27/04/2026 Lunai Bioworks: Of The Original Report To Reflect The Company’s Receipt On April 28, 2026 Of An Additional Staff Determination Letter From The Listing Qualifications Staff Of The Nasdaq Stock Market Llc Regarding Compliance With Nasdaq Listing Rule 5550(b)(2). The Soliciting Material And Related Disclosures Included In The Original Report Under The Captions “the Special Meeting And The Proposals Being Voted On,” “additional Information And Where To Find It” And “participants In The Solicitation,” Are No Longer Applicable Because The Special Meeting Has Been Held And The Proposals Submitted To A Vote Of Stockholders Thereat Have Been Acted Upon
27/04/2026 Lunai Bioworks: Entry Into A Material Definitive Agreement, Completion Of Acquisition Or Disposition Of Assets, Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard; Transfer Of Listing, Unregistered Sales Of Equity Securities, Material Modification To Rights Of Security Holders, Amendments To Articles Of Incorporation Or Bylaws; Change In Fiscal Year, Financial Statements And Exhibits
24/03/2026 Lunai Bioworks: Entry Into A Material Definitive Agreement, Unregistered Sales Of Equity Securities, Other Events, Financial Statements And Exhibits
All organization news

Documentation

IFRS/US GAAP reports

2026
I q eng
2025
I q eng
II q eng
IV q eng
2024
I q eng
II q eng
III q eng
IV q eng
2023
I q eng
II q eng
III q eng
IV q eng
2022
I q eng
II q eng
III q eng
IV q eng
2021
I q eng
II q eng
III q eng
IV q eng
2020
I q eng
II q eng
III q eng
IV q eng
2019
I q eng
II q eng
III q eng
IV q eng
2018
I q eng
II q eng
III q eng
IV q eng
2017
I q eng
II q eng
III q eng
IV q eng
2016
I q eng
II q eng
III q eng
IV q eng
2015
I q eng
II q eng
III q eng
IV q eng
2014
IV q eng
Show all Hide
Authorization required
You need to request access

Stocks

Public debt by currencies

Show more Hide

Codes

  • SIC
    2834 PHARMACEUTICAL PREPARATIONS
  • CIK
    0001527728
  • EIN
    45-2259340
Registration is required to get access.